Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus neoadjuvant chemotherapy for resectable locally advanced oral squamous cell carcinoma (Phase II)
ChiCTR2600128718Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in Oral Mucosal Carcinoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600128718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128718.